Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vutiglabridin (HSG4112) 是一种新型且安全的PON2调节剂,是一个外消旋化合物。Vutiglabridin 是Glabridin 的优化结构类似物,比Glabridin 在减重效果和化学稳定性方面更加优越。Vutiglabridin 通过靶向线粒体对氧磷酶-2改善mptp 诱导的帕金森病小鼠的神经变性。Vutiglabridin 是一种治疗肥胖的临床2期药物,在PD 模型中对对线粒体PON2具有治疗作用。Vutiglabridin 渗透到大脑,结合PON2,恢复1-甲基-4-苯基吡啶(MPP*)诱导的SH-SY5Y 神经母细胞瘤细胞线粒体功能障碍。Vutiglabridin 在小鼠实验中 显著减轻了1-甲基-4苯基-1,2,3,6-四氢吡啶(MPTP)诱导的PD 模型小鼠的运动障碍和多巴胺能神经元损伤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 997 | 现货 | ||
5 mg | ¥ 2,890 | 现货 | ||
10 mg | ¥ 4,990 | 现货 | ||
25 mg | ¥ 7,580 | 现货 | ||
50 mg | ¥ 9,870 | 现货 | ||
100 mg | ¥ 13,800 | 现货 | ||
500 mg | ¥ 27,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,990 | 现货 |
产品描述 | Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability. vutiglabridin ameliorates mptp-induced neurodegeneration in Parkinson's disease mice by targeting mitochondrial paraoxonase-2. Vutiglabridin is a clinical phase 2 drug for the treatment of obesity and has therapeutic effects on p-mitochondrial PON2 in a PD model. vutiglabridin penetrates the brain, binds PON2, and restores 1-methyl-4-phenylpyridine (MPP*)-induced neuroblastoma in SH-SY5Y Vutiglabridin significantly attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dyskinesia and dopaminergic neuronal damage in mice modeled with PD in mouse experiments. |
体内活性 | Vutiglabridin (orally administered with 10, 30, or 100 mg/kg dose for 6 weeks) dose-dependently reduces body weight and normalizes obesity-related parameters in high-fat diet (HFD)-induced obese mice. Led to significant dose-dependent body weight reduction by 4.0 g (8.3%), 10 g (21%), and 19 g (40%), respectively, compared to the 48.1 g body weight of HFD-induced obese mice administered with only the vehicle at 10, 30, and 100 mg/kg. Vutiglabridin fully reverses adiposity in HFD-induced obese mice in a dose-dependent manner.[2] |
别名 | HSG4112 |
分子量 | 354.44 |
分子式 | C22H26O4 |
CAS No. | 1800188-47-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (28.21 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8214 mL | 14.1068 mL | 28.2135 mL | 70.5338 mL |
5 mM | 0.5643 mL | 2.8214 mL | 5.6427 mL | 14.1068 mL | |
10 mM | 0.2821 mL | 1.4107 mL | 2.8214 mL | 7.0534 mL | |
20 mM | 0.1411 mL | 0.7053 mL | 1.4107 mL | 3.5267 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vutiglabridin 1800188-47-9 Metabolism Phosphatase HSG4112 HSG 4112 HSG-4112 Inhibitor inhibitor inhibit